$5.84+5.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $208M to $211M for Fiscal year 2026 — up 4.0% on a year earlier
Just reported
From Cytek Biosciences, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$53.2M
+1.8% y/y
+11% q/q
Guided
—
No guide given
Actual
-$8.4M
Guided
—
No guide given
Full year 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $53.2M | $52.3M | +1.79% |
| Profit | -$6.1M | -$5.5M | -11.30% |
| Free Cash Flow | -$6M | -$4.6M | -30.80% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cytek Biosciences, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Cytek Biosciences, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.